Effectiveness and safety of steady versus intermittent high dose vitamin D supplementation for the prevention of falls and fractures among adults: a protocol for systematic review and network meta-analysis

Banaz Al-khalidi,1 Joycelyne Efua Ewusie,2 Jemila Hamid,3 Samantha Kimball 4

ABSTRACT

Introduction Clinical trials and systematic reviews of trials involving vitamin D supplementation have mainly focused on defining the optimal amount of vitamin D dosage. However, the comparative effectiveness of different dosing schedules (ie, daily vs bolus dosing schedule) has been largely unexplored; and currently, there is no consensus regarding the optimal vitamin D dosing schedule. Our objective is to conduct a systematic review and network meta-analysis (NMA) to evaluate the comparative effectiveness and safety of steady (eg, daily, weekly) and intermittent high-dose (eg, monthly, yearly) vitamin D dosing schedules; and to determine the effectiveness of the various dosing schedules and combinations of treatments.

Methods and analysis We will conduct a systematic search and review of literature from major medical databases (MEDLINE, EMBASE, CINAHL, Cochrane Central Register of Controlled Trials and ClinicalTrials.gov) involving studies that compare vitamin D supplementation alone or in combination with calcium. Only randomised controlled trials (RCTs) will be considered. We will, however, consider various settings (eg, community, institutional care) and study designs (eg, cluster RCTs, cross-over trials). Our primary outcomes include falls and fractures including hip-fracture and non-vertebral fractures. Secondary outcomes will include muscle strength, physical performance, gait and mobility limitation. A Bayesian NMA will be conducted, and the results will be presented in the form of treatment effect estimates and ranking probabilities, with corresponding CIs. Pairwise meta-analysis will also be conducted for studies reporting head-to-head comparisons. Subgroup analysis will be performed with respect to pre-determined subgroups; including vitamin D status as measured by serum 25-hydroxyvitamin D levels, age and follow-up time. Sensitivity analysis will also be conducted for studies reporting head-to-head comparisons. Subgroup analysis will be performed with respect to pre-determined subgroups; including vitamin D status as measured by serum 25-hydroxyvitamin D levels, age and follow-up time. Sensitivity analysis will also be performed with respect to risk of bias.

Ethics and dissemination This study is a systematic review and meta-analysis of published RCTs; therefore, no ethical approval is required. Results will be disseminated through open access peer-reviewed publications.

Strengths and limitations of this study

► This review will be the first of its kind to compare different vitamin D dosage schedules (steady vs intermittent bolus dosing schedule).
► The Bayesian random effect network meta-analysis will be utilised in analysing the direct and indirect treatment effects.
► This systematic review only includes randomised controlled trials (RCTs) that administered oral vitamin D supplementation; the quality of included RCTs will be assessed and a sensitivity analysis will be performed to investigate the effect of study quality on the overall treatment effect.
► This systematic review is limited to articles published in English language.

INTRODUCTION

The risk of falls and fractures is a major concern among the ageing population as it can lead to long-term health complications (eg, disability) and pre-mature mortality. Vitamin D is necessary for bone and muscle health,1 and vitamin D deficiency is a risk factor for falls and hip fractures among older adults.1-2 However, the evidence for the role of vitamin D supplementation in the primary prevention of falls and fractures remains inconclusive.3-6 To date, randomised clinical controlled trials (RCT) have administered different dosages of vitamin D supplementation with and without calcium, and the evidence for the optimal dosage of vitamin D intake is still largely unresolved.7-9 Furthermore, the different vitamin D supplementation schedules (ie, daily vs monthly bolus...
dose) used in previous trials have contributed to the conflicting evidence for the role of vitamin D supplementation in the primary prevention of falls and bone fractures. Although, most RCTs and meta-analyses of RCTs have mainly focused on the optimal amount of vitamin D dosage, studies comparing the effectiveness of different dosage schedules have been largely unexplored.

Currently, there is no consensus regarding the optimal vitamin D dosage schedule (ie, frequent and steady vs intermittent high-dose). Hollis has previously suggested that steady intake of vitamin D may be more beneficial than intermittent high-dose intake because of the difference produced in serum vitamin D and 25-hydroxyvitamin D (25(OH)D) concentrations. A large bolus dose results in a spike in both serum vitamin D and 25(OH)D concentrations and an immediate drop-off in serum vitamin D concentration followed by a more gradual but pronounced drop in 25(OH)D. In contrast, daily dosing schedule results in less pronounced increases and maintains serum vitamin D and 25(OH)D levels over a longer period of time. Yet, numerous trials to date have administered bolus dosage schedules (eg, bimonthly, monthly, once every 3–12 months) to increase compliance. Moreover, many published meta-analyses investigating the effects of vitamin D supplementation on skeletal health outcomes have combined daily, weekly, bi-monthly, monthly and large bolus dosage schedules together with some even including high-dose intramuscular injection. Vitamin D dosage schedule may be an important factor to consider when assessing the totality of evidence for the beneficial role of vitamin D supplementation in relation to skeletal health outcomes.

The overall objective of this study is to conduct a systematic review and network meta-analysis (NMA) to examine comparative effectiveness and safety of frequent and steady dosage of vitamin D versus intermittent high-dose supplementation, taken alone or in combination with calcium, in reducing the risk of falls and fractures, as well as to explore differences in safety and effectiveness of the different vitamin D dosage schedules (eg, daily, weekly, monthly, every 6 months, yearly).

**METHODS**

This protocol is written in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols and is registered with the PROSPERO database (CRD42018112662, available at: http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018112662). Any changes to this protocol will be published in the PROSPERO registration.

**Eligibility criteria**

**Population**

Our study population will include all adults who are 55 years or older or a study population with a mean or median age of 55 years or older, either residing in the community or institutional care settings.

**Interventions**

The following vitamin D dosage schedules will be considered for inclusion in our search and subsequent analyses to evaluate comparative efficacy and safety: daily, weekly, bimonthly, monthly, once every 3–12 months intake of oral vitamin D supplementation. We will consider all studies that administer vitamin D alone (either as a supplement or as a fortified food product), or in combination with calcium. For fortified food products, we will only consider RCTs that have administered a vitamin D fortified food product and compare it to an unfortified version of the same product (eg, fortified cheese as the intervention and unfortified cheese as the comparator) to control for any confounding effect from other nutrients when given as a fortified food product.

**Comparators**

Eligible comparator groups within studies will include placebo or another form, dosage schedules and combination of vitamin D supplements (ie, daily vitamin D supplementation alone or in combination with calcium will be compared with an intermittent high-dose vitamin D supplementation or in combination with calcium).

**Outcomes**

The primary outcomes of treatment efficacy are number of falls, overall fractures, hip fractures, non-vertebral fractures. Secondary outcomes for treatment efficacy will be muscle strength, balance, physical performance, gait and mobility limitations. The primary outcome of treatment safety will be hypercalcaemia. Overall mortality will also be considered as a secondary outcome for treatment safety.

**Study designs**

Only RCTs will be included in our systematic review and evidence synthesis. We will consider all designs (eg, cluster, cross-over, etc) and settings (eg, hospital, outpatient, nursing homes). For crossover studies, due to the possibility of a carry-over effect, the Cochrane guideline and recommendations specific to crossover trial will be considered in our analysis.

**Sensitivity analysis** will also be performed to investigate the effect of such studies in the overall pooled estimates and comparative rankings.

**Information sources and search strategy**

Major medical databases including MEDLINE, EMBASE, CINAHL, Cochrane Central Register of Controlled Trials and ClinicalTrials.gov will be searched systematically to identify all eligible studies. We will also search for additional references through hand-searching the bibliographies of included studies as well as relevant systematic reviews and meta-analyses. Search strategies include various preselected terms and combinations of these terms. These include terms such as vitamin D, vitamin D$_2$, vitamin D$_3$, other terms that are used in our search relate to the primary and secondary outcomes and the combination of the outcomes with interventions. The search strategy along with all combination of terms used in our
search are shown in table 1. All English language studies from conception to 30 April 2018 will be considered; and no restrictions are made on sample size, study period, settings and dosage of vitamin D supplementation. Only human trials involving adults who are 55 years or older or a study population with a mean or median age of 55 years or older will be included.

Data collection and analysis

Data management

All abstracts and full text articles will be uploaded to EndNote (V.7) software and all abstracts will be transferred to excel, where screening questions will be developed and tested for Level I and II assessments based on the inclusion and exclusion criteria.

Study selection

All abstracts of relevant articles will be screened independently by two reviewers (Level I), using the predefined inclusion and exclusion criteria. Our inclusion criteria include RCTs administrating oral dosage of vitamin D supplementation alone or with calcium with no restrictions on the dosage amount of vitamin D or calcium. Studies will be excluded if participants are younger than 55 years of age (mean or median age), study design is observational in nature, and vitamin D is administered via intramuscular injection or vitamin D analogues or combined with other food/drink supplements that are fortified with other nutrients. An initial calibration exercise will be conducted prior to screening to ensure high inter-rater reliability. In these pilot runs, a random sample of 50 included abstracts will be reviewed. Interrater agreement will be calculated, and screening will commence when a percentage agreement of at least 80% is observed. If there is poor-moderate agreement (ie, percentage agreement <80%), the eligibility criteria will be revised, as necessary. Subsequently, each abstract will be screened by two reviewers in duplicate. A similar process will be followed for Level II screening where full texts of the studies retained from the Level I screening will be reviewed. Disagreements at both levels of screening will be resolved by discussion or consultation with a third reviewer.

Data abstraction

Study and arm level data will be extracted from all studies retained from Level II screening. A pilot assessment involving five studies will be conducted by the two reviewers. The data abstraction form will be reviewed and data abstracted on the five studies will be discussed among team members to ensure all relevant data is being extracted accurately and in a consistent manner among individuals performing data abstraction. The data abstraction form will then be modified as appropriate to ensure clarity and agreement by all team members.

Data will be abstracted on study characteristics such as year of publication, authorship, location(s) of study, journal of publication, settings, latitude, follow-up period, study design (eg, cluster RCT, cross-over), total sample size as well as arm level sample size, patient characteristics (eg, average (mean or median) age of study population, gender composition, average body mass index (BMI) (or categories)), living conditions (eg, community dwelling or institution care setting), supplementation details (eg, vitamin D dose, calcium dose, placebo, dosage schedules (eg, daily, weekly, monthly, every 3–12 months), baseline and achieved serum 25(OH)D concentration, if measured. We will also abstract data on the primary and secondary trial-level outcomes associated with supplementation efficacy and safety (eg, falls, injurious falls, overall fractures, hip fractures, non-vertebral fractures, muscle strength, physical performance, gait, mobility limitation, hypercalcaemia, and overall mortality). Data on other relevant comorbidities and treatment related information will also be abstracted (eg, osteoporosis, previous history of fracture, etc). For cluster RCTs, we will also abstract additional information needed to calculate the design effect for making sample size and event level adjustments; these include cluster size, number of clusters, and intraclass correlation coefficient.

Node formation

The various dosage schedules for vitamin D supplementation, as well as combinations with and without calcium will form nodes for the NMA. We anticipate an initial overall network with minimum of three connected nodes (frequent and steady vitamin D vs high-dose intermittent vitamin D vs placebo). Depending on the search results, heterogeneity across the studies, number of studies within each node as well as validity of other assumed assumptions for NMA (eg, connectivity, inconsistency, transitivity), we will perform decomposition of the three nodes according, for instance, to dosage schedules (eg, daily, weekly, monthly, etc) and treatment combination (eg, vitamin D alone or in combination with calcium).

Risk of bias and quality assessment

Two reviewers will independently assess the risk of bias for each included study. This will be done using the Cochrane Risk of Bias Tool.18 Each eligible trial will be assessed for the following domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data addressed and selective reporting.

Outcome and effect measures

All primary and secondary outcomes are binary. As such, our outcomes are reported in the form of event frequency and sample size at an arm level. Since analysis involves Bayesian NMA, the effect size we will use is the OR.19 For studies not reporting event frequency, any effect measure reported (eg, relative risk, risk difference) will be abstracted and converted back to event frequency or to OR.
### Table 1
Search criteria for the systematic review: EMBASE

| Step | Keywords (including MeSH words)                                                                 | Number of papers |
|------|---------------------------------------------------------------------------------------------|------------------|
| 1    | Vitamin D/ or Vitamin D.mp                                                                  | 109,558          |
| 2    | Vitamin D2.mp.(mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word) | 1,760            |
| 3    | Vitamin D3.mp.(mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word) | 14,377           |
| 4    | 1 or 2 or 3                                                                                | 116,444          |
| 5    | Falls.mp.(mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word) | 54,525           |
| 6    | Falls.mp. or falling/                                                                      | 73,654           |
| 7    | 5 or 6                                                                                    | 73,654           |
| 8    | 4 and 7                                                                                   | 2,703            |
| 9    | fractures.mp. or fracture                                                                  | 211,161          |
| 10   | fracture*.mp.(mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word) | 357,706          |
| 11   | 9 or 10                                                                                   | 357,706          |
| 12   | 4 and 11                                                                                  | 15,955           |
| 13   | patient mobility/ or limited mobility/ or Mobility.mp.                                    | 187,679          |
| 14   | mobility.mp.(mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word) | 187,679          |
| 15   | 13 or 14                                                                                  | 187,679          |
| 16   | 4 and 15                                                                                  | 1,046            |
| 17   | endurance/ or grip strength/ or physical performance/ or muscle strength/ or Physical Performance*.mp. or fitness/ | 129,167          |
| 18   | Physical Performance*.mp.(mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word) | 20,383           |
| 19   | 17 or 18                                                                                  | 129,167          |
| 20   | 4 and 19                                                                                  | 1,823            |
| 21   | muscle strength.mp. or muscle strength/                                                    | 57,550           |
| 22   | muscle strength.mp.(mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word) | 57,550           |
| 23   | 21 or 22                                                                                  | 57,550           |
| 24   | 4 and 23                                                                                  | 1,302            |
| 25   | gait/ or gait*.mp.                                                                        | 79,085           |
| 26   | 4 and 25                                                                                  | 641              |
| 27   | mortality*.mp.(mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word) | 125,764          |
| 28   | 4 and 27                                                                                  | 7,397            |
| 29   | 8 or 12 or 16 or 20 or 24 or 26 or 28                                                     | 24,342           |

**Limitations**

Continued
Data synthesis

Data will be first summarised descriptively and with respect to study characteristics, outcomes measures, interventions, patient characteristics as well as other relevant variables. Interventions will be carefully evaluated to clearly identify specific nodes that will be used in the NMA. If feasible (ie, if the network is connected), Bayesian random effects NMA will be conducted to estimate the OR and the corresponding 95% CIs as well as 95% prediction intervals for all comparisons, which will be reported in the form of tables and forest plots.21–22 We will also estimate treatment rankings with respect to comparative effectiveness and safety; and these will be provided in the form of rank plots. Surface under the cumulative ranking probabilities with the corresponding 95% CIs will be estimated for each treatment and with respect to each of the outcomes.23 A rank-heat plot across all outcomes will also be provided.24

Prior to conducting NMA, we will perform preliminary analysis to examine the various assumptions required to ensure validity of NMA results. These include checking assumptions of consistency and elucidating homogeneity. As such, we will first investigate global inconsistencies using the design-by-treatment interaction model.25 If inconsistency is detected, we will explore local inconsistencies using the loop-specific approach.26 Data will also be examined for outliers and for potential data errors. We will also explore methodological and statistical heterogeneity as a well as heterogeneity with respect to study characteristics, outcomes measures, patient population and setting differences. Statistical heterogeneity will be examined using the I^2 statistics from all direct (head-to-head) comparisons. Careful considerations (clinical, methodological and statistical) will be done to optimally create the nodes to avoid introducing heterogeneity to the network because of node formation. If significant heterogeneity and/or inconsistency are detected, we will perform meta-regression to elucidate sources of heterogeneity as well as elucidate heterogeneity with respect to known sources of variability (eg, population differences, risk of bias, design differences). We will also perform subgroup analysis to pool estimates from relatively homogenous groups. Sensitivity analyses will also be performed with respect to studies that are deemed to be sources of heterogeneity.

Pair-wise estimates using Bayesian meta-analysis (MA) will also be provided for all comparisons with direct (head-to-head) evidence.20 If NMA is not feasible, pairwise MA will be conducted for interventions with direct evidence only and the results will be presented in the form of forest plots. We will assess for the transitivity assumption to ensure that potential effect modifiers (eg, age, BMI, care settings, study duration) are balanced on average across treatment comparisons. For studies involving cluster RCTs, data will be adjusted using the design effect prior to performing MA and NMA. Meta-regression and/or subgroup analyses will be performed to examine the effect of various effect modifiers.27 These include age, gender, baseline and achieved serum 25(OH)D concentration, BMI categories, form of vitamin D (eg, D3 vs D2, fortified food vs supplement), co-administration with calcium, comorbidities and settings and study period. We will also conduct sensitivity analysis with respect to risk of bias categories as well as other source of variability revealed from our preliminary analysis to ensure consistency and homogeneity. We will also perform deviance analysis to identify outliers, and sensitivity analysis will be performed to ensure robustness of our results. We will use comparison adjusted funnel plots to investigate presence of publication bias.28

All NMA and MA analyses will be conducted in WinBUGS Bayesian statistical software.29 Results will be reported as OR along with the 95% CIs based on 100 000 Monte Carlo simulations and vague priors. Mode convergence will be assessed by examining the trace and history plots as well as calculating the Gelman-Rubin statistic.30 Forest plots and other data analyses will be performed using appropriate packages in the R statistical software.31

Patient and public involvement

Patients or the public will not be involved in the design or conduct of this study.

ETHICS AND DISSEMINATION

The risk of falls and fractures is a major concern particularly among the ageing population and their caregivers.1 Although vitamin D is necessary for bone and muscle strength, the evidence on the role of vitamin D

Table 1 Continued

| Step | Keywords (including MeSH words)                                                                 | Number of papers |
|------|-----------------------------------------------------------------------------------------------|------------------|
| 30   | limit 29 to (English language and (clinical trial or randomised controlled trial or controlled clinical trial or multicentre study or phase 1 clinical trial or phase 2 clinical trial or phase 3 clinical trial or phase 4 clinical trial)) | 4073             |
| 31   | limit 29 to (English language and (meta-analysis or ‘systematic review’))                     | 944              |
| 32   | 30 or 31                                                                                     | 4634             |
supplementation in preventing falls and fractures remains inconclusive. 3-6,13 The different doses and dosage schedules of vitamin D supplementation used in current RCTs have largely contributed to the conflicting evidence on the effectiveness of vitamin D supplementation for the primary prevention of falls and fractures among older adults. 6,8,10,12,13 Since the dosage amount and dosing schedule of vitamin D supplementation are important factors to consider when assessing the effects of vitamin D on skeletal health outcomes, it is imperative that guidance on the optimal doses and dosage schedules for the prevention of falls and fractures are provided.

This study is the first systematic review comparing steady dose and intermittent high-dose vitamin D dosage schedules. The results will provide comparative effectiveness of these two dosage schedules in relation to risk of falls and fractures among older adults (255 years). Our results will also provide comparative effectiveness and safety of the different supplementation schedules and dosage amounts. The results from this study will facilitate evidence-informed decision making and patient care and will serve as a clinical guideline towards effective dosing schedule for vitamin D in the primary prevention of falls and fractures among older adults.

**Author affiliations**
1. School of Kinesiology and Health Science, York University, Toronto, Ontario, Canada
2. Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
3. Clinical Research Unit, Children’s Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada
4. Research Department, Pure North S’Energy Foundation, Calgary, Alberta, Canada

**Contributors**
Conception (SK and BA), study design (SK, BA, JH), screening and data abstraction (BA and JEE), drafting of protocol (BA, SK, JH, JEE), critical review and editing of protocol (BA, SK, JH, JEE). All authors have read and approved the final protocol. Guarantor of the review (SK).

**Funding**
The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests**
None declared.

**Patient consent for publication**
Not required.

**Ethics approval**
This is a systematic review and meta-analysis of published trials; therefore, no ethical approval is required.

**Provenance and peer review**
Not commissioned; externally peer reviewed.

**Open access**
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**REFERENCES**
1. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of medicine: what clinicians need to know. J Clin Endocrinol Metab 2011;96:53–8.
2. Bischoff-Ferrari HA, Bhasin S, Manson JE, et al. Preventing fractures and falls: a limited role for calcium and vitamin D supplements? JAMA 2018;319:1552–3.
3. Bischoff-Ferrari HA, Willett WC, Orav EJ, et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 2012;367:40–9.
4. Zhao J-G, Zeng X-T, Wang J, et al. Association between calcium or vitamin D supplementation and fracture incidence in community-dwelling older adults. JAMA 2017;318.
5. Avenell A, Mak JCS, O’Connell D. Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. Cochrane Database Syst Rev 2014;(4):CD000227.
6. Bolland MJ, Grey A, Gamble GD, et al. Vitamin D supplementation and falls: a trial sequential meta-analysis. Lancet Diabetes Endocrinol 2014;2:573–80.
7. Heaney RP. Guidelines for optimizing design and analysis of clinical studies of nutrient effects. Nutr Rev 2014;72:48–54.
8. Bouillon R, Van Schoor NM, Gielen E, et al. Optimal vitamin D status: a critical analysis on the basis of evidence-based medicine. J Clin Endocrinol Metab 2013;98:E1283–1304.
9. Bolland MJ. Optimal vitamin D supplementation strategies. Endocrine 2017;56:225–6.
10. Zheng YT, Cui QQ, Hong YM, et al. A meta-analysis of high dose, intermittent vitamin D supplementation among older adults. PLoS One 2015;10:e0115850.
11. Sloyer JD, Camargo CA, Stewart AW, et al. Effect of monthly, high-dose, long-term vitamin D supplementation on central blood pressure parameters: a randomized controlled trial substudy. J Am Heart Assoc 2017;6:e006802.
12. Scragg R, Stewart AW, Waayer D, et al. Effect of monthly high-dose vitamin D supplementation on cardiovascular disease in the vitamin D assessment study. JAMA Cardiol 2017;2.
13. Bolland MJ, Grey A, Avenell A. Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis. Lancet Diabetes Endocrinol 2018;6:847–58.
14. Hollis BW, Wagner CL. Clinical review: the role of the parent compound vitamin D with respect to metabolism and function: why clinical dose intervals can affect clinical outcomes. J Clin Endocrinol Metab 2012;98:4619–28.
15. Jorde R, Grimes G. Serum cholecalciferol may be a better marker of vitamin D status than 25-hydroxyvitamin D. Med Hypotheses 2018;111:61–5.
16. Shameer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;350:g7647.
17. Cochrane Handbook. Cross-over trials, (n.d.). Available: https://handbook-5-1.cochrane.org/chapter_16/16_4_cross_over_trials.htm [Accessed 1 Apr 2019]
18. Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
19. Higgins JP, Whitehead A. Borrowing strength from external trials in a meta-analysis. Stat Med 1996;15:2733–49.
20. Whitehead A. Meta-Analysis of controlled clinical trials. John Wiley & Sons, 2002.
21. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105–24.
22. Ades AE, Sculpher M, Sutton A, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. PharmacoEconomics 2006;24:1–19.
23. Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011;64:163–71.
24. Veroniki AA, Straus SE, Fyraridis A, et al. The rank–heat plot is a novel way to present the results from a network meta-analysis including multiple outcomes. J Clin Epidemiol 2016;78:193–9.
25. Veroniki AA, Vasiliadis HS, Higgins JP, et al. Evaluation of inconsistency in networks of interventions. Int J Epidemiol 2013;42:332–45.
26. Dias S, Welton NJ, Caldwell DM, et al. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010;29:932–44.
27. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–58.
28. Veroniki AA, Huedo-Medina TB, Fontoulaikis KN. Appraising Between-Study homogeneity. Small-Study effects, Moderators, and confounders, in: umbrella Rev. Cham: Springer International Publishing, 2016: 161–88.
29. W. The BUGS project. WinBUGS - MRC Biostatistics Unit, (n.d.). Available: https://www.mrc-bsu.cam.ac.uk/software/bugs/the-bugs-project-winbugs/ [Accessed 12 Oct 2018]
30. Gelman A, Rubin DB. Inference from iterative simulation using multiple sequences. Statist. Sci. 1992;7:457–72.
31. R project for statistical computing, 2018. Available: https://www.r-project.org/ [Accessed 12 Oct 2018]